U.S. Markets closed

Otonomy, Inc. (OTIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4502-0.0198 (-4.21%)
At close: 04:00PM EDT
0.4470 -0.00 (-0.71%)
After hours: 06:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4700
Bid0.4495 x 2200
Ask0.4601 x 800
Day's Range0.4341 - 0.4700
52 Week Range0.2400 - 2.5900
Avg. Volume1,602,667
Market Cap25.518M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.8100
Earnings DateFeb 09, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.63
  • Benzinga

    Otonomy Shares Sink After Stopping Mid-Stage Tinnitus Study

    Otonomy Inc (NASDAQ: OTIC) has announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all time points. The 153-subject study did show a higher response rate than placebo in a prospectively defined patient subgroup with tinnitus duration of fewer than six months (population studied in Phase 1/2 trial). The overall results do not support further development of OTO-313. Also Read: Otonomy Hearing L

  • GlobeNewswire

    Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

    OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical

  • Motley Fool

    Otonomy (OTIC) Q2 2022 Earnings Call Transcript

    Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.